Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury

Last updated: November 12, 2024
Sponsor: University of Zurich
Overall Status: Active - Recruiting

Phase

N/A

Condition

Spinal Cord Injuries

Treatment

VERUM TTNS

SHAM TTNS

Clinical Study ID

NCT03965299
2019-00074
  • Ages > 18
  • All Genders

Study Summary

Most patients with spinal cord injury (SCI) develop neurogenic lower urinary tract dysfunction (NLUTD), one of the most devastating sequelae of SCI which ultimately can lead to renal failure. We urgently need an intervention that prevents NLUTD before irreversible damage occurs. Neuromodulation procedures are a promising avenue so that we investigate the effect of transcutaneous tibial nerve stimulation (TTNS) in patients with acute SCI.

This nationwide randomized, sham-controlled, double-blind multicentre clinical trial includes all SCI centres in Switzerland (Basel, Nottwil, Sion, Zürich). Patients are randomly assigned to VERUM TTNS (active stimulation, n=57) and SHAM stimulation (n=57) groups in a 1:1 allocation using computer-generated permuted block randomisation lists stratified on study centre and lower extremity motor score. Daily 30-minute sessions are performed five times a week during an intervention period of 6-9 weeks. The primary outcome of this study is the success of TTNS to prevent neurogenic DO jeopardizing the upper urinary tract, assessed by urodynamics at 1 year after SCI or any earlier time point if DO treatment is necessary (study end). Secondary outcome measures are bladder diary parameters, clinical symptom scores assessed by standardized and validated questionnaires. Furthermore, neurophysiological and neuroimaging outcome measures are assessed as well as, biochemical and molecular changes. Tertiary outcome measure is the safety of TTNS.

Before the actual start of the TASCI RCT, start-up activities will include a piloting phase on groups of healthy volunteers and patients. The goal during this phase is to evaluate the feasibility of the experimental setup, in particular for the TTNS and SHAM intervention, but also to test the setup of the different pre and post assessments (e.g. neurophysiology and neuroimaging tests). Groups of up to 15 participants each will be enrolled in a few consecutive pilot studies allowing for fine tuning and small adaptations in between, if appropriate.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age >18 years

  • Patients with acute SCI (traumatic SCI and sudden onset (<7 days) non-traumatic SCI)within 40 days after injury

  • Patients with acute SCI at cervical or thoracic level

  • Willing to take part and follow the requirements of the TASCI protocol (up to oneyear after SCI)

  • no percutaneous tibial nerve stimulation (PTNS)

  • no functional electrical stimulation (FES), apart from upper limb FES

  • no electrical muscle stimulation (EMS)

  • Informed Consent

Exclusion

Exclusion Criteria:

  • Contraindications to the investigational product

  • DO with contractions greater than 40 cmH2O at a bladder filling volume of less than 500mL at baseline visit

  • Treatment with antimuscarinics or with mirabegron

  • Known or suspected non-adherence, drug or alcohol abuse

  • Inability to follow the procedures of the study, e.g. due to language problems,psychological disorders, dementia, etc. of the participant

  • Participation in another study with investigational drug or product within the 30days preceding and during the present study

  • Neuromodulation treatment for urological or bowel indication in the last six monthsor ongoing

  • Botulinum toxin injections in the detrusor and/or urethral sphincter in the last sixmonths

  • Bilaterally absent tibial nerve compound muscle action potential (cMAP, amplitude < 1mV)

  • Women who are pregnant or breast feeding

  • Intention to become pregnant during the course of the study

  • Individuals especially in need of protection (according to Research with HumanSubjects published by the Swiss Academy of Medical Sciences [www.samw.ch/en/News/News.html])

  • Enrolment of the investigator, his/her family members, employees and other dependentpersons

  • Pre-existing or concomitant medical condition apart from SCI that might pose asafety issue or would interfere with interpretation of study results or studyconduct (e.g. Parkinson's disease, neurodegenerative disorders including multiplesclerosis and amyotrophic lateral sclerosis, urological malignancies)

Study Design

Total Participants: 114
Treatment Group(s): 2
Primary Treatment: VERUM TTNS
Phase:
Study Start date:
June 19, 2019
Estimated Completion Date:
September 30, 2026

Connect with a study center

  • REHAB Basel

    Basel,
    Switzerland

    Active - Recruiting

  • Swiss Paraplegic Centre

    Nottwil,
    Switzerland

    Active - Recruiting

  • Spinal Cord Injury Department, Clinique romande de réadaption

    Sion,
    Switzerland

    Active - Recruiting

  • Department of Neuro-Urology, Spinal Cord Injury Centre & Research, Balgrist University Hospital

    Zürich, 8008
    Switzerland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.